AIA Group Ltd Has $1.29 Million Position in Illumina, Inc. (NASDAQ:ILMN)

AIA Group Ltd boosted its holdings in Illumina, Inc. (NASDAQ:ILMNGet Rating) by 2.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,737 shares of the life sciences company’s stock after buying an additional 172 shares during the period. AIA Group Ltd’s holdings in Illumina were worth $1,285,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Polen Capital Management LLC raised its holdings in Illumina by 62.0% in the third quarter. Polen Capital Management LLC now owns 4,521,397 shares of the life sciences company’s stock worth $862,637,000 after purchasing an additional 1,731,169 shares during the period. Veritas Asset Management LLP increased its position in shares of Illumina by 150.6% during the second quarter. Veritas Asset Management LLP now owns 1,563,455 shares of the life sciences company’s stock worth $288,239,000 after acquiring an additional 939,671 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of Illumina by 5.4% during the second quarter. Loomis Sayles & Co. L P now owns 3,732,098 shares of the life sciences company’s stock worth $688,050,000 after acquiring an additional 191,341 shares in the last quarter. Federated Hermes Inc. increased its position in shares of Illumina by 240.0% during the first quarter. Federated Hermes Inc. now owns 258,226 shares of the life sciences company’s stock worth $90,225,000 after acquiring an additional 182,272 shares in the last quarter. Finally, First Republic Investment Management Inc. increased its position in shares of Illumina by 147.6% during the third quarter. First Republic Investment Management Inc. now owns 267,399 shares of the life sciences company’s stock worth $51,017,000 after acquiring an additional 159,420 shares in the last quarter. 87.97% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Down 0.6 %

Shares of NASDAQ ILMN opened at $215.15 on Wednesday. The company has a market capitalization of $33.84 billion, a P/E ratio of -8.15 and a beta of 1.14. Illumina, Inc. has a 52-week low of $173.45 and a 52-week high of $371.16. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.72 and a current ratio of 0.93. The company’s 50 day moving average price is $206.96 and its 200-day moving average price is $207.91.

Illumina (NASDAQ:ILMNGet Rating) last released its earnings results on Thursday, November 3rd. The life sciences company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.05. Illumina had a negative net margin of 88.40% and a positive return on equity of 4.36%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.10 billion. Equities analysts forecast that Illumina, Inc. will post 2.23 earnings per share for the current year.

Insider Activity at Illumina

In related news, SVP Susan H. Tousi sold 500 shares of the business’s stock in a transaction on Monday, November 7th. The shares were sold at an average price of $223.65, for a total transaction of $111,825.00. Following the transaction, the senior vice president now owns 40,112 shares in the company, valued at approximately $8,971,048.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, SVP Aimee L. Hoyt sold 871 shares of the business’s stock in a transaction on Monday, January 9th. The shares were sold at an average price of $205.57, for a total transaction of $179,051.47. Following the transaction, the senior vice president now owns 2,796 shares in the company, valued at approximately $574,773.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Susan H. Tousi sold 500 shares of the company’s stock in a transaction on Monday, November 7th. The stock was sold at an average price of $223.65, for a total transaction of $111,825.00. Following the transaction, the senior vice president now owns 40,112 shares in the company, valued at approximately $8,971,048.80. The disclosure for this sale can be found here. Insiders have sold 2,371 shares of company stock worth $499,481 in the last quarter. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Argus downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday. They noted that the move was a valuation call. Canaccord Genuity Group dropped their price objective on shares of Illumina from $330.00 to $300.00 and set a “buy” rating for the company in a research note on Tuesday, January 17th. Scotiabank initiated coverage on shares of Illumina in a research note on Wednesday, January 4th. They issued a “sector perform” rating and a $216.00 price objective for the company. OTR Global upgraded shares of Illumina from a “mixed” rating to a “positive” rating in a research note on Tuesday, December 20th. Finally, Piper Sandler dropped their price objective on shares of Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a research note on Monday, November 14th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $252.84.

About Illumina

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Featured Articles

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.